ArticleBMJ open2025
Efficacy and safety of the blood-based cardioplegia solution Huaxi-1 in cardiopulmonary bypass surgery: protocol for a multicentre randomised controlled trial.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCardioplegia during cardiopulmonary bypass is essential for ensuring a surgical field free of blood and cardiac movement. Numerous cardioplegia solutions are available, but consensus guidelines about the safest or most effective do not exist. The present trial will compare the Huaxi-1 cardioplegia solution, which has been used since 2006 with good results at a major Chinese cardiac centre not involved in this trial, with the widely used Custodiol histidine-tryptophan-ketoglutarate (HTK) solution in terms of safety and efficacy at inducing cardiac arrest and protecting the myocardium during bypass. METHODS AND ANALYSIS: A total of 160 adult patients undergoing elective cardiac surgery requiring cardiopulmonary bypass and cardioplegic arrest will be recruited at four medical centres in China. Recruitment is planned to begin on 1 November 2024, and is expected to conclude by 31 October 2025. Eligible patients will be randomly allocated 1:1 to receive either Huaxi-1 or HTK cardioplegia solution. The primary endpoint is the peak level of high-sensitivity cardiac troponin T (hs-cTnT) within 48 hours after surgery between the two groups. The secondary endpoints include levels of myocardial injury markers such as the creatine kinase-myocardial band (CK-MB) and cardiac troponin I at baseline and at 6, 12, 24 and 48 hours after surgery. The two groups will also be compared in terms of how left ventricular ejection fraction changes from baseline and in terms of the rate of spontaneous cardiac recovery. Data will be analysed using SAS V.9.4. ETHICS AND DISSEMINATION: This trial has been approved by the ethics committees at Guangdong Provincial People's Hospital (lead site) and the three other study sites. The results of the study will be published in peer-reviewed journals and presented at international conferences. TRIAL REGISTRATION NUMBER: ChiCTR2400089689 (www.chictr.org.cn).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.